Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00763555 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT00763555 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 88 participants.
The verdict
NCT00763555, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.
Interventions
- DRUG CD 2027
- DRUG Calcitriol Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00763555
The ClinicalTrials.gov registry entry for NCT00763555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CD 2027 is the first listed.
NCT00763555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00763555 about?
NCT00763555 is a clinical study titled "Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis". This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.
What is the current status of trial NCT00763555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2008-09. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00763555?
The interventions under investigation include: CD 2027 (DRUG), Calcitriol Vehicle (DRUG).
Who is sponsoring clinical trial NCT00763555?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.